Pfizer, Inc.

Equities

PFE

US7170811035

Pharmaceuticals

Market Closed - Nyse 04:00:03 2024-02-23 pm EST 5-day change 1st Jan Change
27.76 USD +0.76% Intraday chart for Pfizer, Inc. +0.51% -3.58%
This article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Guggenheim Initiates Pfizer With Buy Rating, Price Target is $36 MT
Prices for new US drugs rose 35% in 2023, more than the previous year RE
Moderna reports surprise profit, sets out road map for RSV vaccine RE
Everest Medicines' Partner Pfizer Announces European Commission Approves VELSIPITY® for Patients with Moderately to Severely Active Ulcerative Colitis CI
ViiV Says Trial Data Shows Injectable HIV Treatment Cabenuva Has 'Superior Efficacy' Compared With Pills in Some People MT
GSK: 'remarkable' results in HIV treatment CF
ViiV's Long-acting Injectable HIV Drug Shown More Effective than Daily Pills in Phase 3 Study MT
Amazon replaces Walgreens on Dow Jones index RE
China move leaves markets unfazed Our Logo
Pfizer Receives EU Marketing Authorization for Ulcerative Colitis Treatment MT
Pfizer Receives EU Marketing Approval for Ulcerative Colitis Therapy MT
Pfizer: EU green light for treatment of ulcerative colitis CF
Pfizer inflammatory bowel disease drug wins EU approval RE
Pfizer inflammatory bowel disease drug wins European Commission approval RE
Health Care Stocks Pile On Gains -- Health Care Roundup DJ
Global markets live: Airbus, Cisco, BAE, Salesforce, Deere... Our Logo
Pfizer Reportedly Offers $93 Million to Settle Lipitor Antitrust Lawsuit MT
Pfizer agrees to pay $93 million to settle Lipitor antitrust lawsuit RE
Early-Stage Trial of Arvinas, Pfizer's Vepdegestrant Combined With Samuraciclib to Potentially Treat Metastatic Breast Cancer Gets Underway MT
Zoetis 4Q Net Up 14%, Sees 2024 Growth on Strong Pet, Livestock Demand DJ
US, Canadian companies kick off 2024 with layoffs RE
Pfizer partners with UT Southwestern Medical Center CF
US lawmakers call for sanctions on China's WuXi AppTec biotech firm RE
US, Canadian companies kick off 2024 with layoffs RE
Pfizer extends AI collaboration with Saama CF
Chart Pfizer, Inc.
More charts
Pfizer, Inc. is the world's leading pharmaceutical group. Net sales break down by family of products as follows: - primary care products (72.8%): medicines used in internal medicine, vaccines, medicines for the prevention and treatment of Covid-19, antivirals, mRNA-based products, etc.; - specialty care products (13.8%): medicines used in immunology, in hospitals and for the treatment of rare diseases, anti-inflammatory medicines, etc.; - oncology products (12.1%); - other (1.3%). At the end of 2022, the group had more than 35 manufacturing sites worldwide. Net sales are distributed geographically as follows: the United States (42.3%), Europe (21.9%) and other (35.8%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
27.76 USD
Average target price
32.77 USD
Spread / Average Target
+18.06%
Consensus
1st Jan change Capi.
-3.58% 156 B $
+32.01% 693 B $
+21.62% 552 B $
+3.25% 386 B $
+18.74% 328 B $
+14.92% 312 B $
+7.97% 210 B $
-4.95% 209 B $
-3.58% 197 B $
+0.42% 153 B $
Other Pharmaceuticals
  1. Stock
  2. Equities
  3. Stock Pfizer, Inc. - Nyse
  4. News Pfizer, Inc.
  5. Morgan Stanley Adjusts Price Target on Pfizer to $37 From $39, Keeps Equalweight Rating
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance
fermer